

If you experience difficulty viewing this message, you can view it online here.



ResonanceHealth® proudly delivers:



December 2011

In This Issue:

2011 in Review
Distributor Appointment
HepaFat™ Scan
MRI-based Fibrosis Test

278 Stirling Highway
Claremont, Perth
WA, Australia, 6010

PO Box 1135
Nedlands, Perth
WA, Australia, 6909

P: +61 (0) 8 9286 5300

F: +61 (0) 8 9286 1179

W: www.resonancehealth.com

E: info@ferriscan.com

2011 in Review

Resonance Health's FerriScan® service for measuring iron overload has now achieved international recognition as the new gold standard to determine a patient's liver iron concentration.

In North America there are now nearly 40 MRI centres providing the FerriScan® service, with a consequent increase in sales volumes. In September, FDA clearance was gained in the USA for the cardiac T2* service, enabling Resonance Health to provide clinicians with even more information on which to assess a patient's danger of complications from iron-overload.

Internationally, since 1 July 2011, sales volumes for FerriScan® have increased by an average of 30% per month over the same period last year.


Distributor Appointment

A distributor with significant experience in marketing to the haematology sector has been appointed for FerriScan® in the United Arab Emirates, Saudi Arabia and Egypt. These represent significant potential markets for FerriScan® where there is already some knowledge of the service through its use in clinical trials. It is anticipated that further countries in the Middle East will have access to FerriScan® through distributors in 2012.

HepaFat™ Scan



FerriScan® is a non-invasive, MRI-based image analysis service to measure liver iron overload



A map of the liver showing areas of high iron concentration

Resonance Health has lodged a Provisional Patent Application to protect our intellectual property associated with the MRI measurement of fatty liver and registered the HepaFat™ Scan trademark. The Company is currently preparing a submission to the FDA for HepaFat™ Scan and has commenced discussions with interested parties on its potential use and license. HepaFat™ Scan provides greater accuracy in measuring liver fat than any other published method and provides some exciting prospects for commercialisation.

MRI-based Fibrosis Test

The Company has completed the recruitment of patients for its liver fibrosis study aimed at developing an MRI test for assessing liver fibrosis. We look forward to updating our shareholders on the outcome of this work in the New Year. Recent discussions held at the American Association for the Study of Liver Disease (AASLD) Conference confirmed a significant unmet need for accurate, non-invasive methods to measure liver fibrosis. Resonance Health's imaging-based assessment therefore represents a significant opportunity for the Company and our shareholders.

The Board and management of Resonance Health would like to take this opportunity to wish you all the best for the festive season and a safe and happy New Year.

[Click to invite a friend to receive our eNewsletter](#)

[Click to unsubscribe](#)

www.ewnewslettersonline.com